tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Prescott TA et al. A yeast chemical genetics approach identifies the compound 3,4,5-trimethoxybenzyl isothiocyanate as a calcineurin inhibitor. 2014 FEBS Lett. pmid:24374339
Wu Y et al. Increased macrophage activation inhibited by tacrolimus in the kidney of diabetic rats. 2014 Nephron Exp. Nephrol. pmid:25376933
Catalano G et al. Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome. 2014 Transpl. Int. pmid:24606320
Saito K et al. Severe diffuse duodenitis successfully treated with intravenous tacrolimus after colectomy for ulcerative colitis. 2014 Intern. Med. pmid:25366006
Siddiqui A et al. Chemometric methods for the quantification of crystalline tacrolimus in solid dispersion by powder X-ray diffractrometry. 2014 J Pharm Sci pmid:24585357
Uesugi S et al. Calcineurin inhibitors suppress the high-temperature stress sensitivity of the yeast ubiquitin ligase Rsp5 mutant: a new method of screening for calcineurin inhibitors. 2014 FEMS Yeast Res. pmid:25035868
Labrador J et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. 2014 Bone Marrow Transplant. pmid:24566710
Goldberg NR et al. Success with single-agent immunosuppression for multifocal choroidopathies. 2014 Am. J. Ophthalmol. pmid:25194229
Verma M et al. Impact of single immunosuppressive drug withdrawal on lymphocyte immunoreactivity. 2014 J. Surg. Res. pmid:24485875
El-Sheikh AA et al. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. 2014 Transl Res pmid:24486136
Carr L et al. Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode. 2014 Clin. Chem. pmid:24281780
Rehman S et al. Effect of different tacrolimus levels on early outcomes after kidney transplantation. 2014 Ann. Transplant. pmid:24509826
Xie M et al. Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience. 2014 Pediatr Transplant pmid:24283660
Balato A et al. Tacrolimus does not alter the production of several cytokines and antimicrobial peptide in Malassezia furfur-infected-keratinocytes. 2014 Mycoses pmid:24512536
Qin XL et al. In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus. 2014 Drug Metab. Dispos. pmid:24195812
Li CJ et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. 2014 PLoS ONE pmid:24465960
Silva-Cunha A et al. Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. 2014 J Ocul Pharmacol Ther pmid:24199740
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Oellerich M et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. 2014 Ther Drug Monit pmid:24452066
Suarez-Kurtz G et al. Pharmacogenomic implications of population admixture: Brazil as a model case. 2014 Pharmacogenomics pmid:24444410
Kurzawski M et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. 2014 Pharmacogenomics pmid:24444408
Ducroux E et al. Hidradenitis suppurativa after renal transplantation: complete remission after switching from oral cyclosporine to oral tacrolimus. 2014 J. Am. Acad. Dermatol. pmid:25437996
Xue F et al. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients. 2014 Pediatr Transplant pmid:24438215
Chen YK et al. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. 2014 PLoS ONE pmid:25310192
Fuchs U et al. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus. 2014 Transpl. Immunol. pmid:24932812
Zhu X et al. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. 2014 Blood Cells Mol. Dis. pmid:24931461
Han N et al. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. 2014 Basic Clin. Pharmacol. Toxicol. pmid:24238261
Taguchi K et al. False tacrolimus concentrations measured by antibody-conjugated magnetic immunoassay in liver transplant patient: 2 case reports and literature review. 2014 Exp Clin Transplant pmid:24206050
Cho A et al. Calcineurin signaling regulates neural induction through antagonizing the BMP pathway. 2014 Neuron pmid:24698271
Teraki Y [Atopic dermatitis in pregnancy]. 2014 Arerugi pmid:24714179
Rangel EB Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. 2014 Expert Opin Drug Metab Toxicol pmid:25255841
Casey MJ et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. 2014 Transplantation pmid:24717218
Trotter JF and Lizardo-Sanchez L Everolimus in liver transplantation. 2014 Curr Opin Organ Transplant pmid:25254569
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Hirai F et al. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. 2014 J. Gastroenterol. Hepatol. pmid:24033383
Funaro D et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. 2014 J. Am. Acad. Dermatol. pmid:24704090
Doligalski CT et al. Sublingual administration of tacrolimus: current trends and available evidence. 2014 Pharmacotherapy pmid:25251980
Burroughs LM et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. 2014 Biol. Blood Marrow Transplant. pmid:25196857
Ghanem RC et al. Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. 2014 Cornea pmid:25188789
Ricciardelli I et al. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. 2014 Blood pmid:25185261
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Werk AN et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. 2014 Clin. Pharmacol. Ther. pmid:24126681
Chatterjea A et al. Suppression of the immune system as a critical step for bone formation from allogeneic osteoprogenitors implanted in rats. 2014 J. Cell. Mol. Med. pmid:24237965
Mabe S et al. Detecting protein-protein interactions based on kinase-mediated growth induction of mammalian cells. 2014 Sci Rep pmid:25135216
Sol Fustiñana M et al. Protein degradation by ubiquitin-proteasome system in formation and labilization of contextual conditioning memory. 2014 Learn. Mem. pmid:25135196
Takeuchi T et al. Tacrolimus-induced left ventricular apical hypertrophy in a patient with post-allogeneic hematopoietic stem cell transplantation. 2014 Int. J. Cardiol. pmid:25131917
Huang H et al. Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells. 2014 Chin. Med. J. pmid:25131236
Zivčić-Ćosić S et al. Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period. 2014 Int Urol Nephrol pmid:23515930
Wang B et al. Multifaceted interaction of the traditional Chinese medicinal herb Schisandra chinensis with cytochrome P450-mediated drug metabolism in rats. 2014 J Ethnopharmacol pmid:25091466
Hadjipanagi D et al. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population. 2014 BMC Res Notes pmid:24593903
Bao J and Liang H Tacrolimus-induced permanent asymptomatic pontine myelinolysis after liver transplantation. 2014 Intern. Med. pmid:25088893
Yan YH et al. Role of FK506 binding protein 12 in morphine-induced μ-opioid receptor internalization and desensitization. 2014 Neurosci. Lett. pmid:24607931
Purani JM and Purani HJ Treatment of geographic tongue with topical tacrolimus. 2014 BMJ Case Rep pmid:25085945
Kornblit B et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. 2014 Haematologica pmid:25085357
Sethna CB and Gipson DS Treatment of FSGS in Children. 2014 Adv Chronic Kidney Dis pmid:24602468
Bercaw-Pratt JL et al. Clinical recommendation: pediatric lichen sclerosus. 2014 J Pediatr Adolesc Gynecol pmid:24602304
Demmers MW et al. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. 2014 Transplantation pmid:24157471
Kraus TS et al. Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient. 2014 Acta Haematol. pmid:24157860
Hostettler KE et al. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation. 2014 Eur. Respir. J. pmid:23645405
Thapa RK and Yoo BK Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. 2014 J Dermatolog Treat pmid:23210668
Viecelli A et al. Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia. 2014 BMJ Case Rep pmid:25257886
Yamazoe K et al. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine. 2014 Cornea pmid:25255133
Segarra-Medrano A et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. 2014 Nefrologia pmid:25036063
Boschetti G et al. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. 2014 Dig Liver Dis pmid:25023007
John K et al. Role of dendritic cells in the context of acute cellular rejection: comparison between tacrolimus- or cyclosporine A-treated heart transplanted recipients. 2014 Cytometry B Clin Cytom pmid:24668729
Okamoto T et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with febrile urinary tract infection. 2014 Eur. J. Pediatr. pmid:24221606
Personett HA et al. Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. 2014 Transplant. Proc. pmid:25017243
Steinebrunner N et al. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation. 2014 Transpl Infect Dis pmid:24666466
Levinger E et al. Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. 2014 Graefes Arch. Clin. Exp. Ophthalmol. pmid:24696044
GoriaÄ­nov VA et al. [Effect of tacrolimus on the results of living related kidney donor transplantation]. 2014 Ter. Arkh. pmid:25095659
Shilpa PS et al. Topical tacrolimus in the management of oral lichen planus: literature review. 2014 J Calif Dent Assoc pmid:25080722
Kuramitsu S et al. [Case report of introducing MMF and steroids as an immunosuppressive therapy after living-donor liver transplantation for a patient with the diabetic nephropathy]. 2014 Fukuoka Igaku Zasshi pmid:25000660
Kluk J et al. Follicular mucinosis treated with topical 0.1% tacrolimus ointment. 2014 Clin. Exp. Dermatol. pmid:24252117
Matsumoto K et al. [Perioperative agranulocytosis induced by immunosuppressants in a renal graft recipient : a case report]. 2014 Hinyokika Kiyo pmid:25001642
Friedrich RB et al. Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations. 2014 J Biomed Nanotechnol pmid:25016659
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Nomura H et al. A patient with lupus miliaris disseminatus faciei treated successfully with a combination of oral metronidazole and topical tacrolimus. 2014 J. Dermatol. pmid:24931738
Rahman Z et al. Near-infrared and fourier transform infrared chemometric methods for the quantification of crystalline tacrolimus from sustained-release amorphous solid dispersion. 2014 J Pharm Sci pmid:24931728
Kim SH et al. Expression, purification and characterization of soluble recombinant peptidyl-prolyl cis/trans isomerase from Vibrio anguillarum. 2014 Protein Expr. Purif. pmid:24931498
Enderby CY et al. Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study. 2014 Clin Transplant pmid:24931421
Liu Z et al. Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review. 2014 PLoS ONE pmid:25198195
Tran D et al. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. 2014 Exp Clin Transplant pmid:24844288
Feng S et al. A rapidly reversible chemical dimerizer system to study lipid signaling in living cells. 2014 Angew. Chem. Int. Ed. Engl. pmid:24841150
Kahvecioglu S et al. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant. 2014 Exp Clin Transplant pmid:24447269
Doren EL and Aya-ay ML Pyoderma gangrenosum following breast reduction: treatment with topical tacrolimus and steroids. 2014 Aesthet Surg J pmid:24448967
Lin YH and Pratt MR A dual small-molecule rheostat for precise control of protein concentration in Mammalian cells. 2014 Chembiochem pmid:24615791
Hashi S et al. Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. 2014 Transplant. Proc. pmid:24767342
Uemoto S et al. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24767340
Yamanaka M et al. Development and evaluation of a tacrolimus cream formulation using a binary solvent system. 2014 Int J Pharm pmid:24456671
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Muduma G et al. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. 2014 J Med Econ pmid:24754700
Parashos SA et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 2014 JAMA Neurol pmid:24711047
Bloch J et al. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. 2014 Pharmacogenomics pmid:25521359
Chen Y et al. Comparison of long-term impact of immunosuppressants at therapeutic doses on hepatic function and histological changes in unilateral nephrectomized rats. 2014 Exp. Toxicol. Pathol. pmid:25081300
Díaz-García C et al. Pregnancy after allogeneic uterus transplantation in the rat: perinatal outcome and growth trajectory. 2014 Fertil. Steril. pmid:25439799
Ibrahim O et al. The role of infliximab in the treatment of superficial granulomatous pyoderma of the head and neck. 2014 J. Am. Acad. Dermatol. pmid:25438004
Kraaij MD et al. Human monocytes produce interferon-gamma upon stimulation with LPS. 2014 Cytokine pmid:24680476
Sawamoto K et al. Mechanisms of lower maintenance dose of tacrolimus in obese patients. 2014 Drug Metab. Pharmacokinet. pmid:24670405
Xie M et al. Brucellosis infection in an adult liver transplant recipient. 2014 Transpl Infect Dis pmid:24666385
Takazono T et al. Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. 2014 BMC Infect. Dis. pmid:24576098